Cargando…

Ribosome dysfunction underlies SLFN14-related thrombocytopenia

Pathogenic missense variants in SLFN14, which encode an RNA endoribonuclease protein that regulates ribosomal RNA (rRNA) degradation, are known to cause inherited thrombocytopenia (TP) with impaired platelet aggregation and adenosine triphosphate secretion. Despite mild laboratory defects, the patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ver Donck, Fabienne, Ramaekers, Kato, Thys, Chantal, Van Laer, Christine, Peerlinck, Kathelijne, Van Geet, Chris, Eto, Koji, Labarque, Veerle, Freson, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646786/
https://www.ncbi.nlm.nih.gov/pubmed/36790527
http://dx.doi.org/10.1182/blood.2022017712
_version_ 1785134961358012416
author Ver Donck, Fabienne
Ramaekers, Kato
Thys, Chantal
Van Laer, Christine
Peerlinck, Kathelijne
Van Geet, Chris
Eto, Koji
Labarque, Veerle
Freson, Kathleen
author_facet Ver Donck, Fabienne
Ramaekers, Kato
Thys, Chantal
Van Laer, Christine
Peerlinck, Kathelijne
Van Geet, Chris
Eto, Koji
Labarque, Veerle
Freson, Kathleen
author_sort Ver Donck, Fabienne
collection PubMed
description Pathogenic missense variants in SLFN14, which encode an RNA endoribonuclease protein that regulates ribosomal RNA (rRNA) degradation, are known to cause inherited thrombocytopenia (TP) with impaired platelet aggregation and adenosine triphosphate secretion. Despite mild laboratory defects, the patients displayed an obvious bleeding phenotype. However, the function of SLFN14 in megakaryocyte (MK) and platelet biology remains unknown. This study aimed to model the disease in an immortalized MK cell line (imMKCL) and to characterize the platelet transcriptome in patients with the SLFN14 K219N variant. MK derived from heterozygous and homozygous SLFN14 K219N imMKCL and stem cells of blood from patients mainly presented with a defect in proplatelet formation and mitochondrial organization. SLFN14-defective platelets and mature MK showed signs of rRNA degradation; however, this was absent in undifferentiated imMKCL cells and granulocytes. Total platelet RNA was sequenced in 2 patients and 19 healthy controls. Differential gene expression analysis yielded 2999 and 2888 significantly (|log2 fold change| >1, false discovery rate <0.05) up- and downregulated genes, respectively. Remarkably, these downregulated genes were not enriched in any biological pathway, whereas upregulated genes were enriched in pathways involved in (mitochondrial) translation and transcription, with a significant upregulation of 134 ribosomal protein genes (RPGs). The upregulation of mitochondrial RPGs through increased mammalian target of rapamycin complex 1 (mTORC1) signaling in SLFN14 K219N MK seems to be a compensatory response to rRNA degradation. mTORC1 inhibition with rapamycin resulted in further enhanced rRNA degradation in SLFN14 K219N MK. Taken together, our study indicates dysregulation of mTORC1 coordinated ribosomal biogenesis is the disease mechanism for SLFN14-related TP.
format Online
Article
Text
id pubmed-10646786
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-106467862023-02-18 Ribosome dysfunction underlies SLFN14-related thrombocytopenia Ver Donck, Fabienne Ramaekers, Kato Thys, Chantal Van Laer, Christine Peerlinck, Kathelijne Van Geet, Chris Eto, Koji Labarque, Veerle Freson, Kathleen Blood Platelets and Thrombopoiesis Pathogenic missense variants in SLFN14, which encode an RNA endoribonuclease protein that regulates ribosomal RNA (rRNA) degradation, are known to cause inherited thrombocytopenia (TP) with impaired platelet aggregation and adenosine triphosphate secretion. Despite mild laboratory defects, the patients displayed an obvious bleeding phenotype. However, the function of SLFN14 in megakaryocyte (MK) and platelet biology remains unknown. This study aimed to model the disease in an immortalized MK cell line (imMKCL) and to characterize the platelet transcriptome in patients with the SLFN14 K219N variant. MK derived from heterozygous and homozygous SLFN14 K219N imMKCL and stem cells of blood from patients mainly presented with a defect in proplatelet formation and mitochondrial organization. SLFN14-defective platelets and mature MK showed signs of rRNA degradation; however, this was absent in undifferentiated imMKCL cells and granulocytes. Total platelet RNA was sequenced in 2 patients and 19 healthy controls. Differential gene expression analysis yielded 2999 and 2888 significantly (|log2 fold change| >1, false discovery rate <0.05) up- and downregulated genes, respectively. Remarkably, these downregulated genes were not enriched in any biological pathway, whereas upregulated genes were enriched in pathways involved in (mitochondrial) translation and transcription, with a significant upregulation of 134 ribosomal protein genes (RPGs). The upregulation of mitochondrial RPGs through increased mammalian target of rapamycin complex 1 (mTORC1) signaling in SLFN14 K219N MK seems to be a compensatory response to rRNA degradation. mTORC1 inhibition with rapamycin resulted in further enhanced rRNA degradation in SLFN14 K219N MK. Taken together, our study indicates dysregulation of mTORC1 coordinated ribosomal biogenesis is the disease mechanism for SLFN14-related TP. The American Society of Hematology 2023-05-04 2023-02-18 /pmc/articles/PMC10646786/ /pubmed/36790527 http://dx.doi.org/10.1182/blood.2022017712 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Platelets and Thrombopoiesis
Ver Donck, Fabienne
Ramaekers, Kato
Thys, Chantal
Van Laer, Christine
Peerlinck, Kathelijne
Van Geet, Chris
Eto, Koji
Labarque, Veerle
Freson, Kathleen
Ribosome dysfunction underlies SLFN14-related thrombocytopenia
title Ribosome dysfunction underlies SLFN14-related thrombocytopenia
title_full Ribosome dysfunction underlies SLFN14-related thrombocytopenia
title_fullStr Ribosome dysfunction underlies SLFN14-related thrombocytopenia
title_full_unstemmed Ribosome dysfunction underlies SLFN14-related thrombocytopenia
title_short Ribosome dysfunction underlies SLFN14-related thrombocytopenia
title_sort ribosome dysfunction underlies slfn14-related thrombocytopenia
topic Platelets and Thrombopoiesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646786/
https://www.ncbi.nlm.nih.gov/pubmed/36790527
http://dx.doi.org/10.1182/blood.2022017712
work_keys_str_mv AT verdonckfabienne ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT ramaekerskato ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT thyschantal ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT vanlaerchristine ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT peerlinckkathelijne ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT vangeetchris ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT etokoji ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT labarqueveerle ribosomedysfunctionunderliesslfn14relatedthrombocytopenia
AT fresonkathleen ribosomedysfunctionunderliesslfn14relatedthrombocytopenia